Wird geladen...
Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma
Diffuse large B cell lymphoma (dlbcl) is an aggressive non-Hodgkin lymphoma, accounting for approximately 30% of lymphoma cases in Canada. Although most patients will achieve a cure, up to 40% will experience refractory disease after initial treatment, or relapse after a period of remission. In elig...
Gespeichert in:
| Veröffentlicht in: | Curr Oncol |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Multimed Inc.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6726277/ https://ncbi.nlm.nih.gov/pubmed/31548805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.5421 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|